Alexander Cumbo sold $517k of SLDB
President and CEO at Solid Biosciences Inc.. 80,258 shares at an average of $6.44, traded Feb 2, 2026, filed Feb 2, 2026.
Score components
- +25RoleCEO
- +18Trade size$517k at market
- +5Share of holdings soldSold 23% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.5%, 3m +12.4%, 6m +24.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-034087, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 29, 2026 | MOption exercise Common Stock10b5-1 | +169,401 | - | - | 250,789 | Feb 2, 2026 |
| Jan 31, 2026 | MOption exercise Common Stock10b5-1 | +100,400 | - | - | 351,189 | Feb 2, 2026 |
| Feb 2, 2026 | SOpen-market sale Common Stock10b5-1 | -80,258 | $6.44 | $517k | 270,931 | Feb 2, 2026 |
| Jan 29, 2026 | MOption exercise Performance Stock Unitsderivative10b5-1 | -169,401 | $0.00 | $0 | 0 | Feb 2, 2026 |
| Jan 29, 2026 | AGrant or award Employee Stock Option (Right to Buy)derivative10b5-1 | +509,850 | $0.00 | $0 | 509,850 | Feb 2, 2026 |
| Jan 29, 2026 | AGrant or award Restricted Stock Unitsderivative10b5-1 | +254,900 | $0.00 | $0 | 254,900 | Feb 2, 2026 |
| Jan 31, 2026 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -100,400 | $0.00 | $0 | 301,200 | Feb 2, 2026 |
Related signals
Other insiders at Solid Biosciences Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Solid Biosciences Inc. | Alexander Cumbo President and CEO | $97k 16,644 shares | -7% | |
| 0Weak | Solid Biosciences Inc. | Ilan Ganot director | $15k 2,658 shares | -9% | |
| 0Weak | Solid Biosciences Inc. | Jessie Hanrahan Chief Regulatory Officer | $24k 4,134 shares | -5% | |
| 0Weak | Solid Biosciences Inc. | Paul Herzich Chief Technology Officer | $21k 3,616 shares | -5% | |
| 6Weak | Solid Biosciences Inc. | David T Howton Chief Operating Officer | $43k 7,469 shares | -7% | |
| 7Weak | Solid Biosciences Inc. | Kevin Tan CFO & Treasurer | $31k 5,404 shares | -5% | |
| 24Weak | Solid Biosciences Inc. | Gabriel Brooks Chief Medical Officer | $81k 12,616 shares | -13% | |
| 39Weak | Solid Biosciences Inc. | Alexander Cumbo President and CEO | $315k 48,913 shares | -18% | |
| 21Weak | Solid Biosciences Inc. | Ilan Ganot director | $46k 7,205 shares | -22% | |
| 24Weak | Solid Biosciences Inc. | Jessie Hanrahan Chief Regulatory Officer | $80k 12,348 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.